Solid biosciences announces acquisition of aavantibio and concurrent $75 million private placement

- transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current aavantibio ceo, bo cumbo -

SLDB Ratings Summary

SLDB Quant Ranking